Daré Bioscience Stock (NASDAQ:DARE)

Daré Bioscience, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market healthcare solutions specifically for women in the United States. Its comprehensive pipeline addresses a broad spectrum of needs within women's health, encompassing contraception, fertility, and both sexual and vaginal well-being. The company's initial commercial offering is XACIATO, a prescription single-dose vaginal gel designed to treat bacterial vaginosis in female patients from 12 years of age. Daré has established a licensing agreement with Organon & Co. and Organon International GmbH to commercialize this product. Beyond its marketed therapy, Daré boasts a robust development portfolio. In advanced clinical stages, it is progressing Ovaprene, a monthly hormone-free vaginal contraceptive, and Sildenafil Cream, a topical formulation of sildenafil intended for vulvar and vaginal application to manage female sexual arousal disorder. Several programs are primed for Phase 1 clinical trials, including DARE-HRT1, an intravaginal ring delivering a combination of bio-identical estradiol and progesterone for vasomotor symptom management in hormone therapy. Also in this category are DARE-VVA1, a vaginally administered tamoxifen formulation targeting vulvar and vaginal atrophy in patients with hormone-receptor-positive breast cancer; DARE-FRT1, an intravaginal ring containing bio-identical progesterone for both preterm birth prevention and broader luteal phase support during in vitro fertilization; and DARE-PTB1, another intravaginal ring also utilizing bio-identical progesterone for preventing preterm birth. At the pre-clinical level, Daré is exploring innovative solutions such as DARE-LARC1, a combination product aimed at reversible contraception. This stage also includes ADARE-204 and ADARE-214, which are injectable etonogestrel formulations intended to provide contraception for 6-month and 12-month periods, respectively, alongside DARE-RH1, a non-hormonal contraceptive approach for both men and women. Daré Bioscience, Inc. maintains its corporate headquarters in San Diego, California.